Provided by Tiger Trade Technology Pte. Ltd.

Sagimet Biosciences Inc.

9.37
-0.5100-5.16%
Volume:2.01M
Turnover:19.04M
Market Cap:582.43M
PE:-7.50
High:10.01
Open:9.63
Low:9.32
Close:9.88
52wk High:11.45
52wk Low:4.50
Shares:62.16M
Float Shares:62.16M
Volume Ratio:0.80
T/O Rate:3.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2490
EPS(LYR):-1.5800
ROE:-24.37%
ROA:-16.41%
PB:2.27
PE(LYR):-5.93

Loading ...

Sagimet Biosciences Schedules Virtual KOL Event on Denifanstat Acne Program

Reuters
·
Sep 28

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Neogen (NEOG), Larimar Therapeutics (LRMR) and Sagimet Biosciences, Inc. Class A (SGMT)

TIPRANKS
·
Sep 28

Editas, Sagimet, Dropbox, Arcturus, Quanta Trending With Analysts

TIPRANKS
·
Sep 26

Sagimet Biosciences Down over 15%, on Pace for Largest Percent Decrease Since April 2025

Dow Jones
·
Sep 25

Sagimet Biosciences Price Target Announced at $7.00/Share by Goldman Sachs

Dow Jones
·
Sep 24

H.C. Wainwright Remains a Buy on Sagimet Biosciences, Inc. Class A (SGMT)

TIPRANKS
·
Sep 22

Barclays Upgrades Sagimet Biosciences to Overweight From Equalweight, Adjusts Price Target to $18 From $8

MT Newswires Live
·
Sep 09

Sagimet Biosciences Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
Sep 09

Sagimet Biosciences initiated with an Overweight at Cantor Fitzgerald

TIPRANKS
·
Sep 09

Sagimet Biosciences Inc. : Barclays Raises to Overweight from Equal-Weight; Raises Target Price to $18 from $8

THOMSON REUTERS
·
Sep 09

Sagimet Biosciences to Present at Cantor Global Healthcare Conference

Reuters
·
Sep 02

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

GlobeNewswire
·
Sep 02

Sagimet Biosciences Price Target Maintained with a $29.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 25

Sagimet Reiterated as Buy on De-Risked Acne Program and Clearer Regulatory Path; $29 Price Target Maintained

TIPRANKS
·
Aug 25

Sagimet Biosciences advances AURORA clinical trial

TIPRANKS
·
Aug 25

Sagimet Advances Aurora Phase 3 Acne Trial of Denifanstat, Targets Q4 2026 Enrollment

Reuters
·
Aug 25

Sagimet Biosciences Advances Aurora U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026

THOMSON REUTERS
·
Aug 25

Sagimet Biosciences - Patient Screening for Aurora Phase 3 Trial to Begin in October 2026

THOMSON REUTERS
·
Aug 25

Sagimet Biosciences Inc.: Anticipate Submitting an Nda upon Completion of 12-Week Phase of Study

THOMSON REUTERS
·
Aug 25

Sagimet Biosciences - All Clinical Trial Sites Identified and Cro Retained for Aurora Phase 3 Trial

THOMSON REUTERS
·
Aug 25